I
Inter Pharma PCL
SET:IP
Inter Pharma PCL
SET:IP
Price:
4.42
THB
0.91%
Market Cap:
฿2.7B
Balance Sheet
Balance Sheet Decomposition
Inter Pharma PCL
Inter Pharma PCL
Balance Sheet Decomposition is not available for
Inter Pharma PCL
Inter Pharma PCL
Balance Sheet
Inter Pharma PCL
Inter Pharma PCL
Currency: THB
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
9
|
6
|
36
|
32
|
343
|
152
|
174
|
776
|
412
|
0
|
|
| Cash |
9
|
6
|
36
|
32
|
343
|
152
|
174
|
776
|
412
|
0
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
|
| Total Receivables |
10
|
41
|
38
|
84
|
105
|
156
|
293
|
392
|
425
|
447
|
|
| Accounts Receivables |
7
|
14
|
35
|
79
|
90
|
124
|
258
|
340
|
337
|
0
|
|
| Other Receivables |
3
|
27
|
3
|
5
|
15
|
32
|
35
|
52
|
88
|
0
|
|
| Inventory |
3
|
19
|
14
|
56
|
51
|
108
|
192
|
333
|
345
|
330
|
|
| Other Current Assets |
1
|
1
|
1
|
3
|
6
|
1
|
7
|
13
|
20
|
19
|
|
| Total Current Assets |
24
|
68
|
89
|
176
|
505
|
417
|
667
|
1 515
|
1 203
|
982
|
|
| PP&E Net |
5
|
5
|
7
|
11
|
10
|
255
|
457
|
881
|
929
|
1 150
|
|
| PP&E Gross |
5
|
5
|
7
|
11
|
10
|
255
|
457
|
881
|
929
|
0
|
|
| Accumulated Depreciation |
2
|
4
|
3
|
3
|
4
|
38
|
54
|
298
|
339
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
1
|
49
|
55
|
168
|
197
|
204
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
22
|
22
|
478
|
478
|
478
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
6
|
6
|
5
|
5
|
0
|
10
|
9
|
44
|
134
|
|
| Other Long-Term Assets |
0
|
1
|
3
|
4
|
5
|
13
|
116
|
39
|
23
|
30
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
22
|
22
|
478
|
478
|
478
|
|
| Total Assets |
29
N/A
|
80
+177%
|
105
+31%
|
195
+87%
|
526
+169%
|
756
+44%
|
1 327
+75%
|
3 090
+133%
|
2 952
-4%
|
3 021
+2%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
2
|
13
|
7
|
43
|
17
|
59
|
70
|
194
|
201
|
185
|
|
| Accrued Liabilities |
1
|
0
|
0
|
13
|
8
|
12
|
16
|
35
|
47
|
46
|
|
| Short-Term Debt |
0
|
0
|
0
|
12
|
9
|
11
|
131
|
49
|
46
|
80
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
16
|
36
|
103
|
93
|
82
|
|
| Other Current Liabilities |
3
|
20
|
17
|
20
|
22
|
63
|
83
|
118
|
92
|
134
|
|
| Total Current Liabilities |
7
|
33
|
24
|
87
|
56
|
160
|
336
|
498
|
479
|
526
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
93
|
189
|
387
|
260
|
233
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
55
|
59
|
58
|
|
| Minority Interest |
0
|
9
|
5
|
6
|
10
|
17
|
22
|
190
|
205
|
217
|
|
| Other Liabilities |
0
|
1
|
2
|
1
|
4
|
16
|
19
|
33
|
36
|
49
|
|
| Total Liabilities |
8
N/A
|
43
+469%
|
31
-27%
|
95
+203%
|
70
-26%
|
286
+308%
|
565
+97%
|
1 164
+106%
|
1 039
-11%
|
1 084
+4%
|
|
| Equity | |||||||||||
| Common Stock |
5
|
5
|
40
|
65
|
103
|
103
|
149
|
186
|
186
|
303
|
|
| Retained Earnings |
16
|
32
|
33
|
36
|
66
|
80
|
139
|
260
|
247
|
154
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
0
|
287
|
287
|
474
|
1 480
|
1 480
|
1 480
|
|
| Total Equity |
21
N/A
|
37
+73%
|
73
+98%
|
101
+37%
|
456
+353%
|
470
+3%
|
762
+62%
|
1 926
+153%
|
1 913
-1%
|
1 937
+1%
|
|
| Total Liabilities & Equity |
29
N/A
|
80
+177%
|
105
+31%
|
195
+87%
|
526
+169%
|
756
+44%
|
1 327
+75%
|
3 090
+133%
|
2 952
-4%
|
3 021
+2%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
10
|
14
|
113
|
183
|
290
|
290
|
484
|
605
|
605
|
605
|
|
Switch to:
Switch to:
See Also
Discover More
